Independent Prognostic Value of Lipocalin-2 in Congenital Heart Disease-associated Pulmonary Artery Hypertension

Overview

Journal World J Cardiol

Publisher Baishideng Publishing Group

Specialty Cardiology & Vascular Diseases

Date 2024 Dec 30

PMID 39734824

Authors

Zhang-Ke Guo

Ping-Gui Chen

Yao-Xuan Li

Hong Jiao

Xiao-Hui Kong

Song Bai

Xiao-Feng Li

Ai-Jun Liu

Guo-Liang Wang

Affiliations

Soon will be listed here.

Abstract

Background: Timely and accurate evaluation of the patient's pulmonary arterial pressure (PAP) is of great significance for the treatment of congenital heart disease. Currently, there is no non-invasive gold standard method for evaluating PAP.

Aim: To assess the prognostic value of lipocalin-2 (LCN2) in relation to PAP in patients with congenital heart disease associated with pulmonary artery hypertension.

Methods: We conducted a retrospective analysis of 69 pediatric patients diagnosed with ventricular septal defects. The patients' clinical and laboratory data were collected. The serum LCN2 concentrations were compared between the pulmonary arterial hypertension (PAH) group and the nonPAH group. The correlation of LCN2 concentration with PAH classification was evaluated using binary logistic regression analysis. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic potential of LCN2 for PAH.

Results: Serum LCN2 concentration significantly correlated with patients' mean PAP ( = 0.544, < 0.001), but not correlated with creatinine ( = 0.446) or blood urea nitrogen ( = 0.747). LCN2 levels were significantly correlated with PAH in both univariate [odds ratio (OR) 1.107, 95%CI: 1.033-1.185, = 0.004)] and multivariate regression analysis (OR 1.150, 95%CI: 1.027-1.288, = 0.015). ROC curve analysis revealed an area under the curve of 0.783 for LCN2. At the cutoff value of 19.42 ng/mL, the sensitivity and specificity of LCN2 for diagnosing PAH is 90.19% and 55.56%, respectively. LCN2 concentration also significantly correlated with the post-repair mean PAP in patients with congenital heart disease ( = 0.532, = 0.009).

Conclusion: LCN2 is emerging as a candidate biomarker for assessing PAP in patients with congenital heart disease. Its high sensitivity in diagnosing PAH makes it a valuable tool in patient management.

References

van Riel A, Schuuring M, van Hessen I, Zwinderman A, Cozijnsen L, Reichert C . Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol. 2014; 174(2):299-305. DOI: 10.1016/j.ijcard.2014.04.072. View

Jone P, Ivy D, Hauck A, Karamlou T, Truong U, Coleman R . Pulmonary Hypertension in Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circ Heart Fail. 2023; 16(7):e00080. DOI: 10.1161/HHF.0000000000000080. View

Hongsawong N, Khamdee P, Silvilairat S, Chartapisak W . Prevalence and associated factors of renal dysfunction and proteinuria in cyanotic congenital heart disease. Pediatr Nephrol. 2017; 33(3):493-501. DOI: 10.1007/s00467-017-3804-3. View

Goetz D, Holmes M, Borregaard N, Bluhm M, Raymond K, Strong R . The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002; 10(5):1033-43. DOI: 10.1016/s1097-2765(02)00708-6. View

Zhao R, Wei P, Sun X, Zhang D, He Q, Liu J . Role of lipocalin 2 in stroke. Neurobiol Dis. 2023; 179:106044. DOI: 10.1016/j.nbd.2023.106044. View

Wang G, Liu X, Meng L, Liu S, Wang L, Li J . Up-regulated lipocalin-2 in pulmonary hypertension involving in pulmonary artery SMC resistance to apoptosis. Int J Biol Sci. 2014; 10(7):798-806. PMC: 4115200. DOI: 10.7150/ijbs.9470. View

Jung B, Park Y, Yoon B, Bae J, Han S, Heo J . Reduced secretion of LCN2 (lipocalin 2) from reactive astrocytes through autophagic and proteasomal regulation alleviates inflammatory stress and neuronal damage. Autophagy. 2023; 19(8):2296-2317. PMC: 10351455. DOI: 10.1080/15548627.2023.2180202. View

Wang G, Liu S, Wang L, Meng L, Cui C, Zhang H . Lipocalin-2 Promotes Endoplasmic Reticulum Stress and Proliferation by Augmenting Intracellular Iron in Human Pulmonary Arterial Smooth Muscle Cells. Int J Biol Sci. 2017; 13(2):135-144. PMC: 5332868. DOI: 10.7150/ijbs.17758. View

Jaberi S, Cohen A, DSouza C, Abdulrazzaq Y, Ojha S, Bastaki S . Lipocalin-2: Structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021; 142:112002. DOI: 10.1016/j.biopha.2021.112002. View

10.

Wang G, Ma N, Meng L, Wei Y, Gui J . Activation of the phosphatidylinositol 3-kinase/Akt pathway is involved in lipocalin-2-promoted human pulmonary artery smooth muscle cell proliferation. Mol Cell Biochem. 2015; 410(1-2):207-13. DOI: 10.1007/s11010-015-2553-5. View

11.

Sun W, Lou K, Chen L, Liu S, Pang S . Lipocalin-2: a role in hepatic gluconeogenesis via AMP-activated protein kinase (AMPK). J Endocrinol Invest. 2021; 44(8):1753-1765. DOI: 10.1007/s40618-020-01494-0. View

12.

van Donge T, Staub E, Atkinson A, Gotta V, van den Anker J, Risch L . Age appropriate reference intervals for eight kidney function and injury markers in infants, children and adolescents. Clin Chem Lab Med. 2020; 59(2):373-382. DOI: 10.1515/cclm-2020-0781. View

13.

Wang G, Liu S, Kong X, Jiao H, Tong F, Guo Z . Lipocalin-2 induced LDHA expression promotes vascular remodelling in pulmonary hypertension. Cell Prolif. 2024; 57(12):e13717. PMC: 11628741. DOI: 10.1111/cpr.13717. View

14.

Simonneau G, Montani D, Celermajer D, Denton C, Gatzoulis M, Krowka M . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018; 53(1). PMC: 6351336. DOI: 10.1183/13993003.01913-2018. View

15.

Gist K, Kwiatkowski D, Cooper D . Acute kidney injury in congenital heart disease. Curr Opin Cardiol. 2017; 33(1):101-107. DOI: 10.1097/HCO.0000000000000473. View

16.

Kim K, Lee J, Shin H, Jeong E, Jang H, Ahn Y . Lipocalin-2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high-fat diet-fed Ob/Ob mice. Hepatology. 2022; 77(3):888-901. PMC: 9936980. DOI: 10.1002/hep.32569. View

17.

Marakala V . Neutrophil gelatinase-associated lipocalin (NGAL) in kidney injury - A systematic review. Clin Chim Acta. 2022; 536:135-141. DOI: 10.1016/j.cca.2022.08.029. View

18.

Marassi M, Fadini G . The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023; 22(1):195. PMC: 10391899. DOI: 10.1186/s12933-023-01937-x. View

19.

Kunz M, Gotzinger F, Emrich I, Schwenger V, Bohm M, Mahfoud F . Cardio-renal interaction - Clinical trials update 2022. Nutr Metab Cardiovasc Dis. 2022; 32(11):2451-2458. DOI: 10.1016/j.numecd.2022.07.002. View

20.

Farmakis I, Demerouti E, Karyofyllis P, Karatasakis G, Stratinaki M, Tsiapras D . Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?. J Clin Med. 2021; 10(13). PMC: 8268493. DOI: 10.3390/jcm10132826. View